Today, we are faced with a plethora of social issues such as an aging society, increasing lifestyle-related diseases, and soaring medical costs. However, due to the enormous cost, time, and effort involved in new drug development, these issues are not being adequately addressed. This is because the conventional new drug development methods using cultured cells, mice, and patient samples make it difficult to achieve an efficient drug discovery process. Instead, we use Drosophila (fruit flies), which is easy, fast, and inexpensive to raise and breed, has no ethical hurdles, and has similar genes and drug responses to mammals. Specifically, we provide drug discovery support services and licenses for in-house developed lead compounds for various diseases such as cancer, heart disease, stroke, rheumatism, and diabetes.
Based on research results from Hokkaido University (Sonoshita Lab, Komatsuzaki Lab), the University of Tokyo (Goda Lab), and the Icahn School of Medicine at Mount Sinai (Cagan Lab), we are currently in preparation for launching the company with the support of the Japan Science and Technology Agency (JST)'s START program, the Japan Agency for Medical Research and Development (AMED)'s drug discovery program, and the Japan Society for the Promotion of Science (JSPS)'s core-to-core program.